Publicacións (111) Publicacións de Luis Miguel Antón Aparicio

2024

  1. Parvimonas micra can translocate from the subgingival sulcus of the human oral cavity to colorectal adenocarcinoma

    Molecular Oncology, Vol. 18, Núm. 5, pp. 1143-1173

  2. The multispecies microbial cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a precision biomarker for colorectal cancer diagnosis

    Molecular Oncology, Vol. 18, Núm. 5, pp. 1093-1122

2021

  1. Signaling pathways in CRC

    Foundations of Colorectal Cancer (Elsevier), pp. 519-528

2020

  1. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus

    Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1565-1579

2019

  1. “Oncofrail”: Oncología en la fragilidad. Desde la reflexión ética a la práctica clínica

    Eidon: revista de la fundación de ciencias de la salud, Núm. 51, pp. 4-15

2018

  1. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies

    Expert Opinion on Drug Safety, Vol. 17, Núm. 6, pp. 573-579

2017

  1. Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy

    Clinical and Translational Oncology, Vol. 19, Núm. 10, pp. 1175-1182

2016

  1. Medicina paliativa: libro del curso de "Especialista en cuidados paliativos" dir.

    Trama

  2. Role of taxanes in advanced prostate cancer

    Clinical and Translational Oncology, Vol. 18, Núm. 10, pp. 972-980

2015

  1. Circulating miR-200c and miR-141 and outcomes in patients with breast cancer

    BMC Cancer, Vol. 15, Núm. 1

  2. Clinical implications of epithelial cell plasticity in cancer progression

    Cancer Letters, Vol. 366, Núm. 1, pp. 1-10

  3. Cáncer colorrectal: un modelo darwiniano de inmuno-selección celular

    Abordaje multidisciplinar de cáncer colorrectal (Andavira), pp. 453-470

  4. Células madre y cáncer de colon

    Abordaje multidisciplinar de cáncer colorrectal (Andavira), pp. 425-438

  5. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: A retrospective cross-sectional analysis

    BMC Cancer, Vol. 15, Núm. 1

  6. Radium-223 dichloride: A new paradigm in the treatment of prostate cancer

    Expert Review of Anticancer Therapy, Vol. 15, Núm. 3, pp. 339-348

  7. Side effects of targeted therapy

    Springer New York, pp. 377-416

  8. Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors

    Redox biology, Vol. 5, pp. 422

  9. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors

    Redox Biology, Vol. 6, pp. 421-425

  10. Vías de señalización en cáncer de colon

    Abordaje multidisciplinar de cáncer colorrectal (Andavira), pp. 439-452

2014

  1. Cabazitaxel for metastatic castration-resistant prostate cancer: Safety data from the Spanish expanded access program

    Expert Opinion on Drug Safety, Vol. 13, Núm. 9, pp. 1165-1173